First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide

Real‐world data are limited on tenofovir alafenamide (TAF). We aimed to study TAF real‐world outcomes with other first‐line regimens for chronic hepatitis B (CHB). We enrolled patients with CHB from 10 centers retrospectively and followed them for 36 months prospectively. We analyzed switching patte...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Calvin Q., Afdhal, Nezam H., Ankoma‐Sey, Victor, Bae, Ho, Curry, Michael P., Dieterich, Douglas, Frazier, Lynn, Frick, Andrew, Hann, Hie‐Won, Kim, W. Ray, Kwo, Paul, Milligan, Scott, Tong, Myron J., Reddy, K. Rajender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315121/
https://www.ncbi.nlm.nih.gov/pubmed/35445803
http://dx.doi.org/10.1002/hep4.1964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315121/
https://www.ncbi.nlm.nih.gov/pubmed/35445803
http://dx.doi.org/10.1002/hep4.1964

Ejemplares similares